These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 19147587)

  • 1. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.
    Kim RH; Coates JM; Bowles TL; McNerney GP; Sutcliffe J; Jung JU; Gandour-Edwards R; Chuang FY; Bold RJ; Kung HJ
    Cancer Res; 2009 Jan; 69(2):700-8. PubMed ID: 19147587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.
    Savaraj N; Wu C; Li YY; Wangpaichitr M; You M; Bomalaski J; He W; Kuo MT; Feun LG
    Oncotarget; 2015 Mar; 6(8):6295-309. PubMed ID: 25749046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.
    Bowles TL; Kim R; Galante J; Parsons CM; Virudachalam S; Kung HJ; Bold RJ
    Int J Cancer; 2008 Oct; 123(8):1950-5. PubMed ID: 18661517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.
    Thongkum A; Wu C; Li YY; Wangpaichitr M; Navasumrit P; Parnlob V; Sricharunrat T; Bhudhisawasdi V; Ruchirawat M; Savaraj N
    Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28587170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ADI, autophagy and apoptosis: metabolic stress as a therapeutic option for prostate cancer.
    Kim RH; Bold RJ; Kung HJ
    Autophagy; 2009 May; 5(4):567-8. PubMed ID: 19276647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.
    Kuo MT; Savaraj N; Feun LG
    Oncotarget; 2010 Aug; 1(4):246-51. PubMed ID: 21152246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-wide CRISPR/Cas9 knockout screening uncovers a novel inflammatory pathway critical for resistance to arginine-deprivation therapy.
    Chu CY; Lee YC; Hsieh CH; Yeh CT; Chao TY; Chen PH; Lin IH; Hsieh TH; Shih JW; Cheng CH; Chang CC; Lin PS; Huang YL; Chen TM; Yen Y; Ann DK; Kung HJ
    Theranostics; 2021; 11(8):3624-3641. PubMed ID: 33664852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM.
    Przystal JM; Hajji N; Khozoie C; Renziehausen A; Zeng Q; Abaitua F; Hajitou A; Suwan K; Want E; Bomalaski J; Szlosarek P; O'Neill K; Crook T; Syed N
    Cell Death Dis; 2018 Dec; 9(12):1192. PubMed ID: 30546006
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino Acid Uptake Measured by [
    Prudner BC; Sun F; Kremer JC; Xu J; Huang C; Sai KKS; Morgan Z; Leeds H; McConathy J; Van Tine BA
    Theranostics; 2018; 8(8):2107-2116. PubMed ID: 29721066
    [No Abstract]   [Full Text] [Related]  

  • 10. Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase.
    Kelly MP; Jungbluth AA; Wu BW; Bomalaski J; Old LJ; Ritter G
    Br J Cancer; 2012 Jan; 106(2):324-32. PubMed ID: 22134507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypoxia-induced nitric oxide production and tumour perfusion is inhibited by pegylated arginine deiminase (ADI-PEG20).
    Burrows N; Cane G; Robson M; Gaude E; Howat WJ; Szlosarek PW; Pedley RB; Frezza C; Ashcroft M; Maxwell PH
    Sci Rep; 2016 Mar; 6():22950. PubMed ID: 26972697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arginine deprivation as a targeted therapy for cancer.
    Feun L; You M; Wu CJ; Kuo MT; Wangpaichitr M; Spector S; Savaraj N
    Curr Pharm Des; 2008; 14(11):1049-57. PubMed ID: 18473854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Promoter methylation of argininosuccinate synthetase-1 sensitises lymphomas to arginine deiminase treatment, autophagy and caspase-dependent apoptosis.
    Delage B; Luong P; Maharaj L; O'Riain C; Syed N; Crook T; Hatzimichael E; Papoudou-Bai A; Mitchell TJ; Whittaker SJ; Cerio R; Gribben J; Lemoine N; Bomalaski J; Li CF; Joel S; Fitzgibbon J; Chen LT; Szlosarek PW
    Cell Death Dis; 2012 Jul; 3(7):e342. PubMed ID: 22764101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
    Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA
    Cancer Res; 2002 Oct; 62(19):5443-50. PubMed ID: 12359751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial.
    Szlosarek PW; Steele JP; Nolan L; Gilligan D; Taylor P; Spicer J; Lind M; Mitra S; Shamash J; Phillips MM; Luong P; Payne S; Hillman P; Ellis S; Szyszko T; Dancey G; Butcher L; Beck S; Avril NE; Thomson J; Johnston A; Tomsa M; Lawrence C; Schmid P; Crook T; Wu BW; Bomalaski JS; Lemoine N; Sheaff MT; Rudd RM; Fennell D; Hackshaw A
    JAMA Oncol; 2017 Jan; 3(1):58-66. PubMed ID: 27584578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells.
    Tsai WB; Aiba I; Long Y; Lin HK; Feun L; Savaraj N; Kuo MT
    Cancer Res; 2012 May; 72(10):2622-33. PubMed ID: 22461507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mono-PEGylated thermostable Bacillus caldovelox arginase mutant (BCA-M-PEG20) induces apoptosis, autophagy, cell cycle arrest and growth inhibition in gastric cancer cells.
    Chung SF; Tam SY; Kim CF; Chong HC; Lee LM; Leung YC
    Invest New Drugs; 2022 Oct; 40(5):895-904. PubMed ID: 35857203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells.
    Yeh TH; Chen YR; Chen SY; Shen WC; Ann DK; Zaro JL; Shen LJ
    Mol Pharm; 2016 Jan; 13(1):262-71. PubMed ID: 26642391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mono-PEGylation of a Thermostable Arginine-Depleting Enzyme for the Treatment of Lung Cancer.
    Chung SF; Kim CF; Kwok SY; Tam SY; Chen YW; Chong HC; Leung SL; So PK; Wong KY; Leung YC; Lo WH
    Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32545874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of acute myeloid leukemia.
    Tsai HJ; Hsiao HH; Hsu YT; Liu YC; Kao HW; Liu TC; Cho SF; Feng X; Johnston A; Bomalaski JS; Kuo MC; Chen TY
    Cancer Med; 2021 May; 10(9):2946-2955. PubMed ID: 33787078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.